de Kaspar et al., 2001 - Google Patents
Antibiotic resistance pattern and visual outcome in experimentally-induced Staphylococcus epidermidis endophthalmitis in a rabbit modelde Kaspar et al., 2001
- Document ID
- 638697631472409552
- Author
- de Kaspar H
- Hoepfner A
- Engelbert M
- Thiel M
- Ta C
- Mette M
- Schulze-Schwering M
- Grasbon T
- Sesma-Vea B
- Casas J
- Iturralde-Goñi R
- Klauss V
- Kampik A
- Publication year
- Publication venue
- Ophthalmology
External Links
Snippet
OBJECTIVE: To study whether the clinical outcome of Staphylococcus epidermidis-induced endophthalmitis in rabbits is related to the antibiotic resistance pattern of the infecting strain. DESIGN: Experimental animal study. PARTICIPANTS: The right eyes of 36 New Zealand …
- 206010014801 Endophthalmitis 0 title abstract description 73
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/006—Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
Similar Documents
Publication | Publication Date | Title |
---|---|---|
de Kaspar et al. | Antibiotic resistance pattern and visual outcome in experimentally-induced Staphylococcus epidermidis endophthalmitis in a rabbit model | |
Clarke et al. | Management of bacterial postoperative endophthalmitis and the role of vitrectomy | |
Pflugfelder et al. | Intravitreal vancomycin: retinal toxicity, clearance, and interaction with gentamicin | |
Elder et al. | A clinicopathologic study of in vitro sensitivity testing and Acanthamoeba keratitis. | |
Donnenfeld et al. | Penetration of topically applied ciprofloxacin, norfloxacin, and ofloxacin into the aqueous humor | |
Tolar et al. | Evaluation of clinical characteristics and bacterial isolates in dogs with bacterial keratitis: 97 cases (1993–2003) | |
Fernandes et al. | Comparison between polymicrobial and fungal keratitis: clinical features, risk factors, and outcome | |
CN109706238B (en) | Method for detecting and treating age-related macular degeneration | |
Wiechens et al. | Retinal toxicity of liposome-incorporated and free ofloxacin after intravitreal injection in rabbit eyes | |
Skryabina et al. | Diagnosis and treatment of fungal keratitis. Part I | |
Haripriya et al. | Nocardia endophthalmitis after cataract surgery: clinicomicrobiological study | |
Pflugfelder et al. | Infectious endophthalmitis | |
Brod et al. | Endophthalmitis: current approaches to diagnosis and therapy | |
Kupferman et al. | Quantitation of bacterial infection and antibiotic effect in the cornea | |
Ormerod et al. | The intraocular environment and experimental anaerobic bacterial endophthalmitis | |
Basti et al. | Nocardial necrotizing scleritis after trauma: successful outcome using cefazolin | |
Das et al. | Current management strategies of acute post-operative endophthalmitis | |
Maxwell et al. | A natural history study of experimental stuphylococcus epidermidis endophthalmitis | |
Saleh et al. | Efficacy of Intravitreal Administrations of Linezolid in an Experimental Model of S. aureus–Related Endophthalmitis | |
De Kaspar et al. | EFFECTS OF INTRAVITREAL CORTICOSTEROID IN THE TREATMENT OF STAPHYLOCOCCUS AUREUS–INDUCED EXPERIMENTAL ENDOPHTHALMITIS | |
Cohen et al. | Intraocular fluid cultures after primary pars plana vitrectomy | |
Okhravi et al. | Assessment of the effect of oral clarithromycin on visual outcome following presumed bacterial endophthalmitis | |
Kermani et al. | Isolated post-operative Aspergillus niger endophthalmitis | |
PARKKARI et al. | The treatment of endophthalmitis after cataract surgery: review of 26 cases | |
Di Lauro et al. | Eye Diseases: Recent Advances, New Perspectives and Therapeutic Options |